Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GENTIC
2023-505570-15-00Phase 2Authorised
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Feb 2024
- Modality
- Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gentamicin in congenital ichthyosis and Hereditary ichthyosis, sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Proportion of patients with VIIS score decrease ≥15% at month 3 vs baseline. Planned start Feb 2024; status: authorised.
02
Drugs
gentamicin
03
Conditions
congenital ichthyosisHereditary ichthyosis
Beyond the preview
Go deeper on 2023-505570-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505570-15-00.